Results 201 to 210 of about 137,029 (384)

Infliximab exerts anti-inflammatory capacity in IBD by induction of apoptosis in monocytes

, 2000
Michael Schmidt, Norbert Luegering, Andreas Luegering, Klaus Schulze‐Osthoff, Hans Gerd Pauels, Wolfram Domschke, Torsten Kucharzik   +6 more
openalex   +1 more source

Effectiveness and Safety of Advanced Dual‐Targeted Therapy in Refractory Perianal Crohn's Disease

United European Gastroenterology Journal, EarlyView.
ABSTRACT Introduction Perianal Crohn's disease (CD) remains challenging to treat despite the increasing number of advanced therapies. Advanced dual‐targeted therapy has emerged as a new treatment option in CD, but no data are available for perianal CD. The aim of this study was to evaluate the effectiveness and safety of advanced dual‐targeted therapy ...
Nadia Fathallah, Mario Pagano, Mohamed Amine Haouari, Amélie Barré, Calina Atanasiu, Edouard Chambenois, Isabelle Nion‐Larmurier, Stéphane Morisset, Julien Kirchgesner, Vincent de Parades   +9 more
wiley   +1 more source

Acrodermatitis continua of Hallopeau: clinical perspectives. [PDF]

, 2019
Acrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular eruption of one or more digits. The condition presents with tender pustules and underlying erythema on the tip of a digit, more frequently arising on a finger than a toe.
Beck, Kristen M, Bhutani, Tina, Liao, Wilson, Ly, Karen, Smith, Mary Patricia, Thibodeaux, Quinn   +5 more
core  

Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complication

, 2000
Lisa Toy, Ellen Scherl, Asher Kornbluth, James F. Marion, Adrian J. Greenstein, Saul G. Agus, Charles D. Gerson, Nathan S. Fox, Daniel H. Present   +8 more
openalex   +1 more source

Gut Microbial Signatures Associated With Clinical Remission in Inflammatory Bowel Disease Treated With Biologics: A Comprehensive Multi‐Cohort Analysis

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims The relationship between gut microbiota and biological treatment response in inflammatory bowel disease (IBD) remains incompletely understood. We sought to characterize microbial signatures associated with clinical remission and develop a prediction model for clinical remission. Methods We analyzed 16 S rRNA gene sequencing
Qingyang Zheng, Yun Zhong, Haifeng Lian, Jieru Zhuang, Lichun Wang, Jianyong Chen, Huaiming Wang, Hui Wang, Xijie Ye, Zicheng Huang, Keli Yang   +10 more
wiley   +1 more source

Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients

, 2000
Elena Ricart, Remo Panaccione, Edward V. Loftus, William J. Tremaine, William J. Sandborn   +4 more
openalex   +1 more source

Successful Desensitization and Therapeutic Use of Infliximab in Adult and Pediatric Crohn's Disease Patients With Prior Anaphylactic Reaction [PDF]

, 2001
Thomas C. Puchner, Subra Kugathasan, Kevin J. Kelly, David G. Binion   +3 more
openalex   +1 more source

Multi‐Omics Analysis of Ileal Mucosa and Mesentery Before and After Ileocecal Resection in Crohn's Disease

United European Gastroenterology Journal, EarlyView.
ABSTRACT Crohn's disease (CD), a type of inflammatory bowel disease (IBD), is a chronic disorder involving any part of the gastrointestinal tract. Ileocecal resection may serve as a more effective treatment option for early CD. However, the potential relationship and mechanisms between the ileocecum and remission induction of CD are still elusive.
Kai Xia, Yiran Jiao, Luoqiu Zhang, Renyuan Gao, Fangtao Wang, Yun Pan, Shuang Cui, Yin Lin, Tianqi Wu, Lin Li, Xiaocai Wu, Yu Ruan, Jing Sun, Lu Yin, Chunqiu Chen, Moubin Lin   +15 more
wiley   +1 more source

Pretreatment with 6-mercaptopurine/azathioprine (6MP/AZA) prolongs clinical response time in Crohn's disease (CD) patients with fistulizing disease (FD) treated with infliximab (INF)

, 2000
Robert Pittman, Lisa Toy, Asher Kornbluth, Daniel H. Present   +3 more
openalex   +1 more source

Differential Outcomes of Early Versus Late Anti‐TNF Therapy in Ulcerative Colitis and Crohn's Disease: A Nationwide Propensity Score‐Matched Cohort Study

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background Early advanced inflammatory bowel disease (IBD) therapy is emphasised to prevent disease progression and restore quality of life. Aims To evaluate the potential advantages of early versus late anti‐tumour necrosis factor (TNF) therapy in patients with IBD.
Shin Ju Oh, Min‐Taek Lee, Ji Eun Kim, Chi Hyuk Oh, Sun‐Young Jung, Chang Kyun Lee   +5 more
wiley   +1 more source